[go: up one dir, main page]

MX2018012085A - Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119. - Google Patents

Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.

Info

Publication number
MX2018012085A
MX2018012085A MX2018012085A MX2018012085A MX2018012085A MX 2018012085 A MX2018012085 A MX 2018012085A MX 2018012085 A MX2018012085 A MX 2018012085A MX 2018012085 A MX2018012085 A MX 2018012085A MX 2018012085 A MX2018012085 A MX 2018012085A
Authority
MX
Mexico
Prior art keywords
heterocyclic
agonist compounds
gpr119 agonist
compounds
gpr119
Prior art date
Application number
MX2018012085A
Other languages
English (en)
Other versions
MX379920B (es
Inventor
Ishwar Patil Rakesh
Pandurang Gunjal Amol
Verma Jeevan
kumar Puneet
Kumar Rai Santosh
Rai Himanshu
Kumar Anil
Original Assignee
Mankind Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mankind Pharma Ltd filed Critical Mankind Pharma Ltd
Publication of MX2018012085A publication Critical patent/MX2018012085A/es
Publication of MX379920B publication Critical patent/MX379920B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La presente invención se refiere a novedosos compuestos de formula (I), procesos de preparación de la misma y composición que comprende dichos compuestos.
MX2018012085A 2016-04-08 2017-04-05 Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119. MX379920B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201611012426 2016-04-08
PCT/IB2017/000466 WO2017175066A1 (en) 2016-04-08 2017-04-05 Heterocyclic gpr119 agonist compounds

Publications (2)

Publication Number Publication Date
MX2018012085A true MX2018012085A (es) 2019-03-06
MX379920B MX379920B (es) 2025-03-11

Family

ID=58772935

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012085A MX379920B (es) 2016-04-08 2017-04-05 Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.

Country Status (14)

Country Link
US (2) US10208030B2 (es)
EP (1) EP3440078B1 (es)
JP (1) JP6810242B2 (es)
CN (1) CN109415359B (es)
AR (1) AR108102A1 (es)
AU (2) AU2017247691B2 (es)
CA (1) CA3020381C (es)
ES (1) ES2929880T3 (es)
MX (1) MX379920B (es)
NZ (2) NZ746950A (es)
RU (1) RU2734500C2 (es)
TW (2) TWI708773B (es)
WO (1) WO2017175066A1 (es)
ZA (1) ZA201807351B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954229B2 (en) * 2016-04-08 2021-03-23 Mankind Pharma Ltd. GPR119 agonist compounds
US10208030B2 (en) * 2016-04-08 2019-02-19 Mankind Pharma Ltd. GPR119 agonist compounds
WO2017184520A1 (en) * 2016-04-18 2017-10-26 Vanderbilt University Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists
CN107879969B (zh) * 2017-12-26 2021-02-19 山东诚汇双达药业有限公司 一种n-苄基-4-哌啶甲酸的合成方法
BR112021026809A2 (pt) 2019-07-08 2022-02-22 Mankind Pharma Ltd Terapia de combinação de agonistas de gpr119 e inibidores de dpp-4
PH12022550949A1 (en) 2019-10-21 2023-07-03 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
JP2023516187A (ja) 2020-02-28 2023-04-18 キャリーオペ，インク． Ｇｐｒ４０アゴニスト
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
CN111517985B (zh) * 2020-05-20 2023-05-12 济南百润医药科技有限公司 4-[(1r)-1-氨基-2-羟基乙基]-3-氟-苯腈的制备方法
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN111978209B (zh) * 2020-09-07 2023-05-30 成都美域高制药有限公司 一种磷酸特地唑胺中间体3-氟-4-溴苯胺的合成方法
JP2024544036A (ja) * 2021-11-29 2024-11-26 オーシャン ユニバーシティ オブ チャイナ イミダゾチアゾール誘導体およびその製造方法と使用
WO2025037213A1 (en) 2023-08-11 2025-02-20 Mankind Pharma Ltd. Pharmaceutical formulations of gpr119 agonists and uses thereof
WO2025037212A1 (en) 2023-08-11 2025-02-20 Mankind Pharma Ltd. Processes for the preparation and purification of a gpr119 agonist compound
WO2025037211A1 (en) 2023-08-11 2025-02-20 Mankind Pharma Ltd. Solid forms of a gpr119 agonist and processes for the preparation thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009205A (es) * 2008-02-22 2010-11-10 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
KR20100134659A (ko) * 2008-03-31 2010-12-23 메타볼렉스, 인코포레이티드 옥시메틸렌 아릴 화합물 및 그것의 사용
US20110160222A1 (en) 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
CN102971311B (zh) 2010-05-06 2015-07-08 百时美施贵宝公司 作为gpr119调节剂的二环杂芳基化合物
CN102432598A (zh) * 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
UY33805A (es) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
EP2665719B1 (en) * 2011-01-21 2016-05-04 Boehringer Ingelheim International GmbH Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders
CN102898400B (zh) * 2011-07-28 2015-04-29 北京韩美药品有限公司 Gpr119激动剂及其应用
NZ630488A (en) 2012-06-12 2016-07-29 Chong Kun Dang Pharm Corp Piperidine derivatives for gpr119 agonist
EA201690888A1 (ru) * 2013-11-14 2016-10-31 Кадила Хелзкэр Лимитед Новые гетероциклические соединения
US10526345B2 (en) * 2016-04-08 2020-01-07 Mankind Pharma Ltd. Compounds as GPR119 agonists
US10208030B2 (en) * 2016-04-08 2019-02-19 Mankind Pharma Ltd. GPR119 agonist compounds

Also Published As

Publication number Publication date
JP2019516782A (ja) 2019-06-20
TWI708773B (zh) 2020-11-01
US10752622B2 (en) 2020-08-25
TWI678367B (zh) 2019-12-01
AU2020203450B2 (en) 2021-07-01
US10208030B2 (en) 2019-02-19
JP6810242B2 (ja) 2021-01-06
US20170291894A1 (en) 2017-10-12
BR112018070664A2 (pt) 2019-02-05
CN109415359B (zh) 2022-03-04
EP3440078B1 (en) 2022-09-28
NZ763528A (en) 2023-06-30
CA3020381A1 (en) 2017-10-12
ES2929880T3 (es) 2022-12-02
AU2017247691A1 (en) 2018-11-01
US20190127363A1 (en) 2019-05-02
NZ746950A (en) 2020-04-24
CN109415359A (zh) 2019-03-01
RU2018138047A3 (es) 2020-05-12
RU2018138047A (ru) 2020-05-12
AU2017247691B2 (en) 2020-02-27
MX379920B (es) 2025-03-11
WO2017175066A1 (en) 2017-10-12
AR108102A1 (es) 2018-07-18
EP3440078A1 (en) 2019-02-13
CA3020381C (en) 2020-12-15
AU2020203450A1 (en) 2020-06-11
RU2734500C2 (ru) 2020-10-19
TW201741309A (zh) 2017-12-01
ZA201807351B (en) 2019-07-31
TW201945361A (zh) 2019-12-01

Similar Documents

Publication Publication Date Title
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
LT3448859T (lt) Pirolpirolo kompozicijos, kaip piruvato kinazės (pkr) aktyvatoriai
CR20180563A (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que lo contienen
EA201891344A1 (ru) Новые агонисты рецептора апелина и способы применения
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
CO2018011105A2 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj)
MX377277B (es) Derivados de fenoximetilo.
EA201992177A1 (ru) Композиции на основе нирапариба
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
CR20180352A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
BR112016028476A8 (pt) compostos, composição, uso de um composto e método para o combate dos fungos nocivos
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
BR112018011526A2 (pt) compostos policíclicos como inibidores da tirosina quinase de bruton
CO2018005753A2 (es) Composición hemostática
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
EA201790570A1 (ru) Модуляторы р2х7
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения